3 Recession-Proof ETFs to Invest in Now
The U.S. gross domestic product (GDP) contracted 0.3% during the…
Sell
37
GTBIF Quote, Financials, Valuation and Earnings
Last price:
$5.54
Seasonality move
:
-4.9%
Day range:
$5.51 - $5.82
52-week range:
$4.63 - $14.30
Dividend yield:
0%
P/E ratio:
26.38x
P/S ratio:
1.17x
P/B ratio:
0.73x
Volume:
270.1K
Avg. volume:
418.3K
1-year change:
-56.75%
Market cap:
$1.3B
Revenue:
$1.1B
EPS (TTM):
$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
$288M | $0.05 | 0.4% | -44.44% | $15.00 |
|
ATNM
Actinium Pharmaceuticals
|
$246.6K | -$0.34 | -100% | -5.26% | $5.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.21 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
$5.54 | $15.00 | $1.3B | 26.38x | $0.00 | 0% | 1.17x |
|
ATNM
Actinium Pharmaceuticals
|
$1.48 | $5.00 | $46.2M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.56 | $0.85 | $3.3M | -- | $0.00 | 0% | 0.15x |
|
NNVC
Nanoviricides
|
$1.32 | -- | $20.6M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.17 | $1.00 | $3.6M | -- | $0.00 | 0% | 1.05x |
|
TOVX
Theriva Biologics
|
$0.53 | $6.00 | $1.5M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
12.47% | -0.251 | 13.25% | 1.37x |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.541 | -- | 9.03x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.186 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | 2.080 | -- | -- |
|
OGEN
Oragenics
|
-- | 3.254 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -2.512 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
$158.1M | $57.1M | 3.58% | 4.17% | 16.85% | $16.1M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$12.6M | -95.08% | -95.08% | -12769.14% | -$12M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
NNVC
Nanoviricides
|
-- | -$2.1M | -- | -- | -- | -$2.2M |
|
OGEN
Oragenics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Green Thumb Industries vs. Competitors
-
Which has Higher Returns GTBIF or ATNM?
Actinium Pharmaceuticals has a net margin of 4.31% compared to Green Thumb Industries's net margin of -11511.11%. Green Thumb Industries's return on equity of 4.17% beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries53.71% $0.04 $2B ATNMActinium Pharmaceuticals-- -$0.37 $36.4M -
What do Analysts Say About GTBIF or ATNM?
Green Thumb Industries has a consensus price target of $15.00, signalling upside risk potential of 170.76%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 237.84%. Given that Actinium Pharmaceuticals has higher upside potential than Green Thumb Industries, analysts believe Actinium Pharmaceuticals is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries9 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is GTBIF or ATNM More Risky?
Green Thumb Industries has a beta of 1.482, which suggesting that the stock is 48.219% more volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.637%.
-
Which is a Better Dividend Stock GTBIF or ATNM?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or ATNM?
Green Thumb Industries quarterly revenues are $294.3M, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. Green Thumb Industries's net income of $12.7M is higher than Actinium Pharmaceuticals's net income of -$11.6M. Notably, Green Thumb Industries's price-to-earnings ratio is 26.38x while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.17x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.17x 26.38x $294.3M $12.7M ATNMActinium Pharmaceuticals-- -- $81K -$11.6M
-
Which has Higher Returns GTBIF or NBY?
NovaBay Pharmaceuticals has a net margin of 4.31% compared to Green Thumb Industries's net margin of -49.65%. Green Thumb Industries's return on equity of 4.17% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries53.71% $0.04 $2B NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About GTBIF or NBY?
Green Thumb Industries has a consensus price target of $15.00, signalling upside risk potential of 170.76%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that Green Thumb Industries has higher upside potential than NovaBay Pharmaceuticals, analysts believe Green Thumb Industries is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries9 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is GTBIF or NBY More Risky?
Green Thumb Industries has a beta of 1.482, which suggesting that the stock is 48.219% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.
-
Which is a Better Dividend Stock GTBIF or NBY?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or NBY?
Green Thumb Industries quarterly revenues are $294.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Green Thumb Industries's net income of $12.7M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Green Thumb Industries's price-to-earnings ratio is 26.38x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.17x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.17x 26.38x $294.3M $12.7M NBYNovaBay Pharmaceuticals0.15x -- $2.4M -$1.2M
-
Which has Higher Returns GTBIF or NNVC?
Nanoviricides has a net margin of 4.31% compared to Green Thumb Industries's net margin of --. Green Thumb Industries's return on equity of 4.17% beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries53.71% $0.04 $2B NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About GTBIF or NNVC?
Green Thumb Industries has a consensus price target of $15.00, signalling upside risk potential of 170.76%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 392.42%. Given that Nanoviricides has higher upside potential than Green Thumb Industries, analysts believe Nanoviricides is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries9 0 0 NNVCNanoviricides0 0 0 -
Is GTBIF or NNVC More Risky?
Green Thumb Industries has a beta of 1.482, which suggesting that the stock is 48.219% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.
-
Which is a Better Dividend Stock GTBIF or NNVC?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or NNVC?
Green Thumb Industries quarterly revenues are $294.3M, which are larger than Nanoviricides quarterly revenues of --. Green Thumb Industries's net income of $12.7M is higher than Nanoviricides's net income of -$2M. Notably, Green Thumb Industries's price-to-earnings ratio is 26.38x while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.17x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.17x 26.38x $294.3M $12.7M NNVCNanoviricides-- -- -- -$2M
-
Which has Higher Returns GTBIF or OGEN?
Oragenics has a net margin of 4.31% compared to Green Thumb Industries's net margin of --. Green Thumb Industries's return on equity of 4.17% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries53.71% $0.04 $2B OGENOragenics-- -$0.27 -- -
What do Analysts Say About GTBIF or OGEN?
Green Thumb Industries has a consensus price target of $15.00, signalling upside risk potential of 170.76%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 493.12%. Given that Oragenics has higher upside potential than Green Thumb Industries, analysts believe Oragenics is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries9 0 0 OGENOragenics0 1 0 -
Is GTBIF or OGEN More Risky?
Green Thumb Industries has a beta of 1.482, which suggesting that the stock is 48.219% more volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.
-
Which is a Better Dividend Stock GTBIF or OGEN?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or OGEN?
Green Thumb Industries quarterly revenues are $294.3M, which are larger than Oragenics quarterly revenues of --. Green Thumb Industries's net income of $12.7M is higher than Oragenics's net income of -$3.3M. Notably, Green Thumb Industries's price-to-earnings ratio is 26.38x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.17x versus 1.05x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.17x 26.38x $294.3M $12.7M OGENOragenics1.05x -- -- -$3.3M
-
Which has Higher Returns GTBIF or TOVX?
Theriva Biologics has a net margin of 4.31% compared to Green Thumb Industries's net margin of --. Green Thumb Industries's return on equity of 4.17% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries53.71% $0.04 $2B TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About GTBIF or TOVX?
Green Thumb Industries has a consensus price target of $15.00, signalling upside risk potential of 170.76%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 1032.29%. Given that Theriva Biologics has higher upside potential than Green Thumb Industries, analysts believe Theriva Biologics is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries9 0 0 TOVXTheriva Biologics1 1 0 -
Is GTBIF or TOVX More Risky?
Green Thumb Industries has a beta of 1.482, which suggesting that the stock is 48.219% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.
-
Which is a Better Dividend Stock GTBIF or TOVX?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or TOVX?
Green Thumb Industries quarterly revenues are $294.3M, which are larger than Theriva Biologics quarterly revenues of --. Green Thumb Industries's net income of $12.7M is higher than Theriva Biologics's net income of -$4.4M. Notably, Green Thumb Industries's price-to-earnings ratio is 26.38x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.17x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.17x 26.38x $294.3M $12.7M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Butterfly Network the Best Small-Cap Stock?
Brought to public trading by an SPAC merger in early…
Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
